CHICAGO, Dec. 1 For difficult to diagnose patients,Breast-Specific Gamma Imaging (BSGI) is found to be a more useful adjunctiveimaging tool than ultrasound for patients who need additional imagingfollowing a questionable mammogram, this according to findings presented todayat the annual meeting of the Radiological Society of North America (RSNA).BSGI is a molecular breast imaging technique that can see lesions independentof tissue density and discover very early stage cancers.
"My colleagues and I found that in women who needed further examinationbeyond mammography in the diagnosis of breast cancer, BSGI offered moredefinitive answers than ultrasound," said Dr. Jean Weigert, Director ofWomen's Imaging at Mandell and Blau M.D.'s PC, in New Britain, Conn.
Dr. Weigert conducted a study comparing BSGI to ultrasound in patients whorequired additional imaging following a mammogram. As part of their diagnosticevaluation, 70 patients had mammography, ultrasound, BSGI and biopsy. BSGI andultrasound had 96 percent and 58 percent sensitivity respectively and 55percent and 43 percent specificity respectively. These results demonstratethat BSGI may be more useful than ultrasound as an adjunctive imagingtechnology to mammography.
BSGI for the study was conducted using a Dilon 6800 Gamma Camera, ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI.With BSGI, the patient receives a pharmaceutical tracing agent that isabsorbed by all the cells in the body. Due to their increased rate ofmetabolic activity, cancerous cells in the breast absorb a greater amount ofthe tracing agent than the normal surrounding tissue and generally appear as"hot spots" on the BSGI image.
Dr. Weigert concluded that, "BSGI provided superior sensitivity andcomparable -- if not better -- specificity in this group of patients withquestionable mammograms requiring additional diagnostic imaging. BSGI may be amore useful modality than ultrasound as an adjunct imaging technology tomammography."
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imagingproducts to market. Dilon's cornerstone product, the Dilon 6800, is ahigh-resolution, small field-of-view gamma camera, optimized to perform BSGI,a molecular breast imaging procedure which images the metabolic activity ofbreast lesions through radiotracer uptake. Many leading medical centers aroundthe country are now offering BSGI to their patients, including: CornellUniversity Medical Center, New York; George Washington University MedicalCenter, Washington, D.C.; and The Rose, Houston.
For more information on Dilon Technologies please visithttp://www.dilon.com.
SOURCE Dilon Technologies Inc.